ReviewJournal of surgical oncology2024
Review of 2022 PSOGI/RENAPE Consensus on HIPEC.
Review in Journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2026Pooled it
- Awareness and attitudes toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among surgical and medical oncologists.Scientific reports · 2026Article
- Underutilization of CRS, HIPEC & PIPAC in peritoneal mesothelioma across a German nationwide cohort.World journal of surgical oncology · 2026Article
- Advances and challenges in the application of prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer.Frontiers in oncology · 2026Review
- The Effect of Different Intraperitoneal Hyperthermic Chemotherapy (HIPEC) Regimens on Serum Electrolyte Levels: A Comparison of Oxaliplatin and Mitomycin C.Medicina (Kaunas, Lithuania) · 2025Article
- What is worth knowing about peritoneal metastases in colorectal cancer?Frontiers in surgery · 2025Review
- Transforming hyperthermic intraperitoneal chemotherapy: using computer simulation to improve HIPEC treatments.Journal of gastrointestinal oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2022 PSOGI (Peritoneal Surface Oncology Group International) and RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing treatment protocols for various peritoneal malignancies. This initiative is critical due to the wide range of technical variations in HIPEC procedures and the resulting need for standardization to ensure consistent and effective patient care and meaningful audit of multicenter data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.